Robert Shafer
Robert Shafer
Professor of Medicine, Stanford University
Verified email at - Homepage
Cited by
Cited by
2011 update of the drug resistance mutations in HIV-1
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ...
Topics in antiviral medicine 19 (4), 156, 2011
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update
DE Bennett, RJ Camacho, D Otelea, DR Kuritzkes, H Fleury, M Kiuchi, ...
PloS one 4 (3), 2009
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
Science (New York, NY) 330 (6010), 1551, 2010
Human immunodeficiency virus reverse transcriptase and protease sequence database
SY Rhee, MJ Gonzales, R Kantor, BJ Betts, J Ravela, RW Shafer
Nucleic acids research 31 (1), 298-303, 2003
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection
PM Small, RW Shafer, PC Hopewell, SP Singh, MJ Murphy, E Desmond, ...
New England Journal of Medicine 328 (16), 1137-1144, 1993
2017 update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...
Topics in antiviral medicine 24 (4), 132, 2016
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
RW Shafer, LM Smeaton, GK Robbins, SW De Gruttola, Victor, Snyder, ...
New England Journal of Medicine 349 (24), 2304-15, 2003
Web resources for HIV type 1 genotypic-resistance test interpretation
TF Liu, RW Shafer
Clinical infectious diseases 42 (11), 1608-1618, 2006
Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance
C Wang, Y Mitsuya, B Gharizadeh, M Ronaghi, RW Shafer
Genome research 17 (8), 1195-1201, 2007
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
RW Shafer, JM Schapiro
AIDS reviews 10 (2), 67, 2008
Genotypic testing for human immunodeficiency virus type 1 drug resistance
RW Shafer
Clinical microbiology reviews 15 (2), 247-277, 2002
Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection.
RW Shafer, DS Kim, JP Weiss, JM Quale
Medicine 70 (6), 384-397, 1991
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
RW Shafer, SY Rhee, D Pillay, V Miller, P Sandstrom, JM Schapiro, ...
Aids 21 (2), 215-223, 2007
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
R Kantor, DA Katzenstein, B Efron, AP Carvalho, B Wynhoven, P Cane, ...
PLoS medicine 2 (4), 2005
HIV-1 antiretroviral resistance
MW Tang, RW Shafer
Drugs 72 (9), e1-e25, 2012
Update of the drug resistance mutations in HIV-1: March 2013
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, RW Shafer, ...
Topics in antiviral medicine 21 (1), 6, 2013
Rationale and uses of a public HIV drug‐resistance database
RW Shafer
The Journal of infectious diseases 194 (Supplement_1), S51-S58, 2006
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
AK Iversen, RW Shafer, K Wehrly, MA Winters, JI Mullins, B Chesebro, ...
Journal of virology 70 (2), 1086-1090, 1996
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study
DW Haas, LM Smeaton, RW Shafer, GK Robbins, GD Morse, L Labbé, ...
The Journal of infectious diseases 192 (11), 1931-1942, 2005
Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade
RW Shafer, BR Edlin
Clinical infectious diseases 22 (4), 683-704, 1996
The system can't perform the operation now. Try again later.
Articles 1–20